Genetic variation and cognitive dysfunction in opioid-treated patients with cancer.

ABSTRACT:

Background and purpose

The effects of single-nucleotide polymorphisms (SNPs) on the cognitive function of opioid-treated patients with cancer until now have not been explored, but they could potentially be related to poor functioning. This study aimed at identifying associations between SNPs of candidate genes, high opioid dose, and cognitive dysfunction.

Methods

Cross-sectional multicenter study (European Pharmacogenetic Opioid Study, 2005-2008); 1586 patients; 113 SNPs from 41 genes.

Inclusion criteria

cancer, age ≥18 year, opioid treatment, and available genetic data. Cognitive assessment by Mini-Mental State Examination (MMSE).

Analyses

SNPs were rejected if violation of Hardy-Weinberg equilibrium (P < 0.0005), or minor allele frequency <5%; patients were r

SUBMITTER: Kurita GP 

PROVIDER: S-EPMC4864175 | biostudies-literature | 2016 Jul

REPOSITORIES: biostudies-literature